Vimarsana
Biggest News Aggregation in the World

Page 6 - Mathilde Bohin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mathilde Bohin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mathilde Bohin Today - Breaking & Trending Today

Oncodesign Confirms Its Very Good Results in 2021 and an Attractive Outlook For 2022 - Vimarsana News

Oncodesign Confirms Its Very Good Results in 2021 and an Attractive Outlook For 2022

Group turnover up by 23% at €31.3 millionOperating income and revenue of €36.2M, offsetting the foreseen discontinuation of the GSK subsidy (€8M)R&D investments amounting to €7.4MNet profit/loss near the break-even point (-€0.3M)Service BU:Very strong organic growth in external turnover at +31%, reaching €27.6M,EBIT...

Oncodesign ONCODESIGN: Oncodesign Confirms Its Very Good Results in 2021 and an Attractive Outlook For 2022 - Vimarsana News

Oncodesign ONCODESIGN: Oncodesign Confirms Its Very Good Results in 2021 and an Attractive Outlook For 2022

Group turnover up by 23% at €31.3 million Operating income and revenue of €36.2M, offsetting the foreseen discontinuation of the GSK subsidy (€8M) R&D investments amounting to €7.4M

IMPLANET Reports Its 2021 Financial Results and Reviews Its Transformative Year - Vimarsana News

IMPLANET Reports Its 2021 Financial Results and Reviews Its Transformative Year

Successful strategic repositioning: strengthening of the Spine business (+62% in 2021) with the acquisition of OSD and divestment of MADISONTM Sharp increase of 46% in the gross margin, to

IMPLANET Announces the First Surgical Operations in the United States with the ORIGIN Cervical Plate - Vimarsana News

IMPLANET Announces the First Surgical Operations in the United States with the ORIGIN Cervical Plate

First synergies with OSD products in the United States Strengthening of Implanet's presence in the U.S. Spine market Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168,

SEngine Precision Medicine and Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment for Aggressive and Untreatable Tumors - Vimarsana News

SEngine Precision Medicine and Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment for Aggressive and Untreatable Tumors

Collaboration combines SEngine's PARIS Test platform for drug screening on live patient-derived tumor cells and Oncodesign's Nanocyclix technology for generation of novel kinase inhibitors Regulatory